Swiss National Bank Has $201.91 Million Stake in Allergan plc (AGN)

Swiss National Bank lessened its stake in Allergan plc (NYSE:AGN) by 0.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,234,286 shares of the company’s stock after selling 3,900 shares during the quarter. Swiss National Bank’s holdings in Allergan were worth $201,905,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Affinity Investment Advisors LLC increased its stake in shares of Allergan by 4.8% in the 4th quarter. Affinity Investment Advisors LLC now owns 62,184 shares of the company’s stock valued at $10,172,000 after purchasing an additional 2,875 shares in the last quarter. California Public Employees Retirement System increased its stake in shares of Allergan by 3.2% in the 4th quarter. California Public Employees Retirement System now owns 718,800 shares of the company’s stock valued at $117,581,000 after purchasing an additional 22,526 shares in the last quarter. Boston Family Office LLC increased its stake in shares of Allergan by 12.1% in the 4th quarter. Boston Family Office LLC now owns 4,622 shares of the company’s stock valued at $756,000 after purchasing an additional 500 shares in the last quarter. SFE Investment Counsel purchased a new position in shares of Allergan in the 4th quarter valued at about $240,000. Finally, Hyman Charles D purchased a new position in shares of Allergan in the 4th quarter valued at about $206,000. 80.23% of the stock is owned by institutional investors and hedge funds.

In other news, insider William Meury sold 11,807 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $173.89, for a total value of $2,053,119.23. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Christopher J. Coughlin purchased 10,000 shares of the company’s stock in a transaction dated Tuesday, December 5th. The stock was bought at an average price of $163.30 per share, with a total value of $1,633,000.00. The disclosure for this purchase can be found here. Insiders bought 17,630 shares of company stock valued at $2,890,057 over the last 90 days. Company insiders own 0.36% of the company’s stock.

Several equities analysts recently weighed in on AGN shares. JPMorgan Chase & Co. restated a “buy” rating and issued a $275.00 price target on shares of Allergan in a research note on Monday, October 16th. Credit Suisse Group set a $243.00 price target on Allergan and gave the company an “outperform” rating in a research note on Tuesday, October 17th. UBS Group set a $255.00 price target on Allergan and gave the company a “buy” rating in a research note on Tuesday, October 17th. Deutsche Bank set a $251.00 price target on Allergan and gave the company a “buy” rating in a research note on Tuesday, October 17th. Finally, Zacks Investment Research lowered Allergan from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have assigned a buy rating to the stock. Allergan has a consensus rating of “Buy” and an average price target of $227.23.

Shares of Allergan plc (NYSE:AGN) opened at $162.77 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.04 and a quick ratio of 1.08. The stock has a market capitalization of $54,134.54, a P/E ratio of -12.13, a PEG ratio of 1.17 and a beta of 1.19. Allergan plc has a 52-week low of $157.70 and a 52-week high of $256.80.

Allergan (NYSE:AGN) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.74 by $0.12. The business had revenue of $4.33 billion during the quarter, compared to analyst estimates of $4.28 billion. Allergan had a positive return on equity of 8.28% and a negative net margin of 26.32%. The business’s revenue was up 12.0% compared to the same quarter last year. During the same period in the prior year, the business earned $3.90 earnings per share. sell-side analysts predict that Allergan plc will post 15.56 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 28th. Stockholders of record on Wednesday, February 28th will be given a $0.72 dividend. This is a positive change from Allergan’s previous quarterly dividend of $0.70. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.77%. Allergan’s dividend payout ratio is -20.86%.

ILLEGAL ACTIVITY WARNING: “Swiss National Bank Has $201.91 Million Stake in Allergan plc (AGN)” was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.com-unik.info/2018/02/11/swiss-national-bank-has-201-91-million-stake-in-allergan-plc-agn.html.

About Allergan

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit